Gut Inflammation Triggered Dormant Cancer Cell Growth
Researchers found that gut inflammation can stimulate dormant breast cancer cells to reactivate in a mouse model.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Should patients monitor systemic inflammation levels as a way to potentially lower their cancer relapse risk?
A study from the Francis Crick Institute reveals that gut inflammation causes bone marrow reorganization, which can accidentally trigger dormant cancer cells to divide. This research highlights how distant inflammatory events may facilitate the reactivation of cancer cells that have spread to the bones.
Why it matters
Understanding the link between systemic inflammation and cancer reactivation provides a potential window for early medical intervention. This finding suggests that monitoring patients for inflammatory triggers after remission could help identify periods of heightened risk.
The study identified higher levels of HMGB2 molecules in human bone samples where breast and prostate cancer cells were actively dividing. Researchers used skeletal stem cells to create an artificial bone marrow model to test these interactions.
The players
Francis Crick Institute
This is a biomedical research center in London dedicated to understanding the fundamental biology underlying human health and disease.
The details
To replicate the bone marrow environment, researchers grew bone tissue beneath the skin and induced intestinal colitis in mice. The resulting inflammation prompted a reorganization of the bone marrow to boost immune cell production, which inadvertently stimulated dormant metastatic cancer cells to begin growing.
Timeline
The study was published in Cell Reports on October 1, 2026.
The Big Picture
This finding shifts the scientific focus toward how systemic inflammatory responses influence the survival and reactivation of dormant cancer cells in the bone marrow. It challenges the traditional view of metastasis by showing how non-cancerous events elsewhere in the body can directly drive localized cancer progression.
While this research was conducted in animal models, it emphasizes the importance of managing inflammation and infections for patients in remission. Future medical interventions could eventually focus on monitoring bone marrow health to intercept cancer reactivation before it spreads.
The takeaway
This study underscores that cancer management may eventually require a more holistic approach that accounts for systemic inflammation. Patients should consult their oncologists about managing inflammatory conditions during post-treatment recovery.
Further reading
For more information on the latest developments in tumor biology, visit the Cancer section.
More information
View the original Cell Reports study on metastatic dormancy for detailed research findings.
Source note: This article includes information reported by SciTechDaily.
Live Poll
Should patients monitor systemic inflammation levels as a way to potentially lower their cancer relapse risk?
